NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 560 participants.
Also called NCT02305485
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 560 participants
- Registry
-
NCT02305485
-
- Other papers using this trial's data
- 5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized Trial
- A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02305485. Randomized; single masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
- Condition
- Coronary Artery Disease
- Intervention (Device)
- NeoVas BCS
- Intervention (Device)
- XIENCE PRIME EECSS
- Lead sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Record details
- Record id
cardio:ct-nct02305485- Content hash
50e9ec61af2671760ae0c7fa41f9625453d95d4f732cfa898a2be2919a1045b2